HC Wainwright Reaffirms “Buy” Rating for OnKure Therapeutics (NASDAQ:OKUR)

HC Wainwright reaffirmed their buy rating on shares of OnKure Therapeutics (NASDAQ:OKUR) in a report issued on Tuesday,Benzinga reports. They currently have a $34.00 price target on the stock. HC Wainwright also issued estimates for OnKure Therapeutics’ Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.56) EPS, Q1 2026 earnings at ($1.01) EPS, Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($4.19) EPS.

OKUR has been the topic of a number of other research reports. Evercore ISI began coverage on OnKure Therapeutics in a report on Wednesday, April 30th. They set an “outperform” rating on the stock. Zacks Research lowered OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $32.33.

OnKure Therapeutics Stock Performance

OKUR opened at $2.81 on Tuesday. OnKure Therapeutics has a one year low of $1.70 and a one year high of $20.00. The stock’s fifty day moving average is $2.43 and its 200-day moving average is $3.15. The company has a market capitalization of $38.02 million, a PE ratio of -0.59 and a beta of 0.40.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.09. On average, equities research analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Hedge Funds Weigh In On OnKure Therapeutics

Several hedge funds have recently added to or reduced their stakes in OKUR. Geode Capital Management LLC acquired a new position in OnKure Therapeutics in the fourth quarter valued at about $659,000. Renaissance Technologies LLC acquired a new stake in shares of OnKure Therapeutics during the fourth quarter worth $408,000. Barclays PLC bought a new position in shares of OnKure Therapeutics in the fourth quarter worth $75,000. XTX Topco Ltd bought a new position in OnKure Therapeutics in the fourth quarter valued at about $160,000. Finally, Boothbay Fund Management LLC bought a new position in OnKure Therapeutics in the fourth quarter valued at about $671,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.